A new COVID-19 subvariant called NB.1.8.1 — nicknamed “Nimbus” — has become the dominant strain circulating in the United States, accounting for an estimated 43% of sequenced COVID cases as of late June 2026, according to CDC genomic surveillance data. As the variant’s prevalence climbs and wastewater surveillance detects rising viral levels in 10 states, health officials are urging high-risk individuals to confirm their vaccine status before the summer season reaches its peak.
National COVID activity remains low overall, according to the CDC’s July 6 respiratory illness summary. However, the pattern of a new dominant variant emerging alongside rising wastewater signals in multiple states is consistent with the early stages of the summer COVID waves that have occurred every year since 2020.
Why This Matters
Most healthy adults who contract Nimbus will experience mild illness: a sore throat, fatigue, and a few days of upper respiratory symptoms. For that population, this story is a watch-and-prepare notice, not an emergency alert.
But for adults 65 and older, immunocompromised individuals, and people with multiple chronic conditions — the groups that have consistently faced the highest risk of serious COVID illness since the pandemic began — the early weeks of a summer wave are the window during which preventive action is most effective. Waiting until wastewater levels are at their highest means the option to get vaccinated or stock antiviral medications ahead of an infection has passed.
The pattern from Asia, where Nimbus drove earlier surges in China, Singapore, and parts of Southeast Asia, offers a preview: the variant is highly transmissible and capable of fueling large community waves, even if it does not appear to cause more severe illness than other recent Omicron descendants.
What We Know So Far
NB.1.8.1 is a descendant of the JN.1 Omicron lineage. First detected globally in early 2025, it was identified in the United States through airport screening programs in March 2026. By late June, CDC nowcast data showed it had surpassed all other circulating variants to account for approximately 43% of U.S. COVID cases.
The World Health Organization has classified NB.1.8.1 as a “Variant Under Monitoring” — one step below a Variant of Interest and two steps below a Variant of Concern. This classification reflects elevated surveillance attention but does not indicate evidence of increased severity or vaccine escape sufficient to require an emergency response.
Wastewater surveillance through the CDC’s National Wastewater Surveillance System (NWSS) currently shows low national COVID viral activity, but 10 states are reporting high or very high levels: Alabama, Alaska, California, Delaware, Florida, Hawaii, Kentucky, Louisiana, and Texas, according to MedicalDaily’s earlier reporting and CDC wastewater data.
According to the CDC’s epidemic trend tracker, as of June 30, 2026, COVID infections were growing or likely growing in 9 states, declining or likely declining in 22, and stable in 19. The CDC’s July 6 respiratory data summary described COVID activity as “low in most areas of the country.”
Where the Risk Is Highest
Wastewater signals are most elevated in the South and West — regions the CDC identified in its 2026 Summer Outlook as most likely to see a summer COVID surge, in part because of lower population immunity from limited COVID circulation the prior winter.
States currently showing high or very high wastewater COVID viral activity include California, Florida, Texas, Alabama, Louisiana, and Hawaii. These states collectively represent large populations of both high-risk older adults and high-volume summer tourism, creating conditions for rapid spread.
California and Florida stand out as particularly high-exposure states given their large populations, dense urban centers, and high volumes of domestic and international summer travel through Los Angeles, San Francisco, Miami, and Orlando. Texas cities — particularly Houston, Dallas, and San Antonio — are also in states with active wastewater signals.
What Doctors and Experts Say
Dr. Albert Ko, professor of public health, epidemiology, and medicine at the Yale School of Public Health, told TODAY.com that the wastewater and clinical data together indicate a real increase in COVID transmission.
The CDC and WHO have both reviewed the available data from Asia, where Nimbus caused large surges, and have not identified evidence of increased severity compared to prior Omicron strains. Clinical outcome data specific to the U.S. population is still accumulating, as the variant only recently became dominant.
One notable symptom pattern associated with Nimbus in patient reports from Asia and early U.S. cases is a severe sore throat — described by some patients as a “razor blade throat” sensation — that appears earlier and more intensely than with prior variants. This symptom is consistent with other Omicron subvariants but appears to be more pronounced in some Nimbus cases.
What the Evidence Shows — and What It Does Not
The 43% variant proportion figure carries an important caveat: the CDC notes that its precision in variant proportion reporting is currently “low” due to limited genomic sequencing data. This means the exact figure may shift as more samples are submitted and processed.
What is well-established: NB.1.8.1 is now the dominant U.S. variant. What is still accumulating: U.S.-specific clinical severity data.
The WHO and CDC have not found evidence of vaccine escape sufficient to cause widespread serious illness in vaccinated populations. Currently approved COVID vaccines are expected to remain effective against NB.1.8.1.
MedicalDaily Evidence Check:
- Variant classification: Variant Under Monitoring (WHO) — not Variant of Concern
- U.S. variant share: ~43% of sequenced cases as of late June 2026 (CDC precision: low)
- Wastewater: Low nationally; 10 states reporting high or very high levels
- Epidemic growth: Growing in 9 states, declining in 22, stable in 19 as of June 30 (CDC Rt tracker)
- Severity: Available data from Asia suggest no increased severity vs. prior Omicron variants
- What remains unknown: Full U.S. clinical severity profile; whether Nimbus-specific vaccine updates will be needed
- What readers should know: National activity is currently low. High-risk individuals should confirm vaccine status and antiviral access now, before any wave peaks.
Who Faces the Greatest Risk?
COVID risk stratification has not changed with this variant. Based on established CDC clinical guidance and available data:
- Adults 65 and older — at highest risk for hospitalization and death from COVID, regardless of variant
- Immunocompromised individuals, including transplant recipients, people undergoing cancer treatment, and those on biologics or high-dose corticosteroids
- Adults 12 to 64 with multiple chronic conditions — particularly cardiovascular disease, chronic kidney disease, diabetes, and COPD
- People who have not received any COVID vaccine in more than 12 months
- Residents of the 10 states reporting high or very high wastewater activity, particularly those who fall into any of the above categories
For healthy adults under 65 without underlying conditions, the risk of serious illness from Nimbus is low based on available data.
Symptoms and Warning Signs to Watch For
Nimbus symptoms appear to be broadly similar to other recent Omicron variants. Commonly reported symptoms include:
- Sore throat, which some patients describe as unusually severe
- Fatigue and low energy
- Fever or chills
- Nasal congestion or runny nose
- Headache
- Cough
- Muscle aches
Loss of taste and smell — a hallmark of earlier COVID strains — is less common with Omicron subvariants but may still occur in some cases.
Most healthy adults recover at home within five to seven days with rest and hydration.
Seek medical care if you experience: Difficulty breathing, chest pain or pressure, confusion, inability to stay awake or stay alert, bluish lips, or any symptoms that worsen rapidly after an initial period of mild illness. These are warning signs of serious disease requiring urgent evaluation.
For high-risk individuals who test positive, contact a health care provider within the first two days of symptoms to discuss antiviral treatment options, as effectiveness depends on early administration.
What You Can Do Now
- Verify your COVID vaccine status. The 2025-2026 updated vaccines are available for adults 65 and older and for people ages 12 to 64 with at least one underlying health condition. If you are in a high-risk group and have not been vaccinated in more than 12 months, speak with your health care provider about timing.
- Monitor wastewater levels in your state at the CDC NWSS state tracker, updated weekly. Rising levels in your state can signal increasing community transmission before clinical cases are confirmed.
- Know how to access Paxlovid or other antivirals before you need them. For eligible patients, antiviral treatment must begin within five days of symptom onset to be most effective. Confirm your eligibility and where to obtain a prescription in advance.
- Wear a well-fitting mask in crowded indoor settings if you are high-risk and live in or are traveling to a high-activity state during peak summer travel season.
- If you test positive, notify close contacts, isolate per CDC guidance, and contact a health care provider promptly if you are in a high-risk group.
- Avoid contact with high-risk family members — particularly elderly relatives — if you develop respiratory symptoms, even before testing.
Cost and Access: What Patients Should Know
For adults 65 and older, COVID vaccines are covered by Medicare Part B at no cost-sharing. For adults 12 to 64 with underlying conditions, most private insurance plans cover updated COVID vaccines.
Paxlovid (nirmatrelvir-ritonavir) remains the primary antiviral treatment for eligible high-risk patients and is covered by most insurance plans. For uninsured patients, the Pfizer patient assistance program and federally qualified health centers can help with access. Paxlovid requires a prescription; contact your health care provider or use a telehealth service to obtain one quickly if you test positive.
COVID vaccines are available at pharmacies, physician offices, and community health centers nationwide. Use the Vaccines.gov locator to find the nearest available appointment.
What Happens Next
The CDC updates COVID wastewater and variant proportion data weekly. The 2025-2026 updated COVID vaccines targeting the LP.8.1 variant are currently available. Health authorities are monitoring whether a Nimbus-specific vaccine update will be needed for the fall 2026 cycle.
National COVID hospitalization rates remain low and are showing a declining trend, according to the CDC’s July 6 data summary. However, the CDC acknowledged that “it remains possible that there could be larger increases this summer, particularly if a variant that the immune system no longer recognizes becomes more common.”
MedicalDaily will report on significant changes in wastewater trends, hospitalization data, and any updates to vaccine guidance as the summer season progresses.
The Bottom Line
The Nimbus variant (NB.1.8.1) is now the dominant COVID strain in the United States, and early-warning wastewater signals are rising in 10 states — mostly in the South and West. National activity remains low, and current evidence does not support concern about increased severity compared to other recent Omicron variants. High-risk individuals — particularly adults 65 and older, immunocompromised people, and those with multiple chronic conditions — should verify their vaccine status and confirm access to antiviral treatment now, before any summer wave peaks. For most healthy adults, the appropriate response is awareness and monitoring, not alarm.
